"Aliados por la Salud" is a collaboration between Roche, Salud Digna and BBVA working to improve early HPV diagnosis and prevent cervical cancer. This multi-sectoral partnership is paving the way to better health. Nearly 600,000 molecular HPV tests have already been used to fight cancer, and more to come. Find out more at: http://spkl.io/6040fKzYy
Info
Roche ist ein globales Unternehmen mit Vorreiterrolle in der Erforschung und Entwicklung von Medikamenten und Diagnostika und ist darauf fokussiert, Menschen durch wissenschaftlichen Fortschritt ein besseres, längeres Leben zu ermöglichen. Dank der Kombination von Pharma und Diagnostika unter einem Dach ist Roche führend in der personalisierten Medizin - einer Strategie mit dem Ziel, jeder Patientin und jedem Patienten die bestmögliche Behandlung zukommen zu lassen. Roche ist das grösste Biotech-Unternehmen weltweit mit differenzierten Medikamenten für die Onkologie, Immunologie, Infektionskrankheiten, Augenheilkunde und Erkrankungen des Zentralnervensystems. Roche ist auch der bedeutendste Anbieter von In-vitro-Diagnostika und gewebebasierten Krebstests und ein Pionier im Diabetesmanagement. Seit der Gründung im Jahr 1896 erforscht Roche bessere Wege, um Krankheiten zu verhindern, zu erkennen und zu behandeln und leistet einen nachhaltigen Beitrag zur gesellschaftlichen Entwicklung. Zum Ziel des Unternehmens gehört es durch Kooperationen mit allen relevanten Partnern den Zugang von Patienten zu medizinischen Innovationen zu verbessern. Auf der Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation stehen heute 30 von Roche entwickelte Medikamente, darunter lebensrettende Antibiotika, Malariamittel und Krebsmedikamente. Ausgezeichnet wurde Roche zudem bereits das neunte Jahr in Folge als das nachhaltigste Unternehmen innerhalb der Pharma-, Biotechnologie- und Life-Sciences-Branche im Dow Jones Sustainability Index. Die Roche-Gruppe mit Hauptsitz in Basel, Schweiz ist in über 100 Ländern tätig und beschäftigte 2017 weltweit rund 94 000 Mitarbeiterinnen und Mitarbeiter. Im Jahr 2017 investierte Roche CHF 10,4 Milliarden in Forschung und Entwicklung und erzielte einen Umsatz von CHF 53,3 Milliarden. Genentech in den USA gehört vollständig zur Roche-Gruppe. Roche ist Mehrheitsaktionär von Chugai Pharmaceutical, Japan. Weitere Informationen finden Sie unter www.roche.com/careers #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalizedHealthcare #GreatPlaceToWork #Innovation
- Website
-
http://www.roche.com/
Externer Link zu Roche
- Branche
- Biotechnologieforschung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Switzerland 🇨🇭
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Spezialgebiete
- biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data und Science
Orte
Beschäftigte von Roche
Updates
-
We’re thrilled to be a part of the Quad #CancerMoonshot initiative, which brings together the collective power of the United States, Australia, India, and Japan to conquer cervical cancer in the Indo-Pacific region by: 🟦 Supercharging health infrastructure 🟦 Enhancing research collaborations 🟦 Building robust data systems 🟦 Advancing cancer prevention, detection, treatment, and care Did you know #cervicalcancer is the third leading cause of cancer deaths among women in this region? But there's hope—it’s preventable and treatable. Our efforts will focus on: 🟦 Promoting life-saving #HPV vaccinations 💉 🟦 Making screenings more accessible 🩺 🟦 Bringing advanced treatment options to underserved areas 🏥 We’re partnering with Jhpiego and the Department of Health (Philippines) to raise awareness about cervical cancer screening. By spreading the word about HPV testing and the risks of cervical cancer, we aim to provide broad access to high-performance HPV tests and thermal ablation treatment in urban areas of the Philippines. 🎯 Together, we can save countless lives over the next few decades. This initiative is a part of our larger commitment to reducing cancer worldwide. Let’s make a difference together—one step at a time: http://spkl.io/6046fzbSj
-
As #WorldAlzheimersMonth comes to a close, we are reminded that the fight against this disease doesn’t stop. A diagnosis is often the first step in fighting back against Alzheimer’s for the people living with this devastating condition and their families and so much negative stigma still surrounds it. At Roche, we hope to create a tomorrow where an Alzheimer’s diagnosis is the first step towards effective treatment, helping to preserve what makes us who we are. Watch Helen’s story here 👉 http://spkl.io/6042fKTKe Alzheimer Europe #Alzheimers #dementia #WAM
-
Today marks #WorldHeartDay, which aims to raise understanding of cardiovascular diseases The leading preventable cause of cardiovascular diseases is hypertension. Curious to know more? Read the reflections Manu Chakravarthy MD, PhD Global Head of Cardiovascular, Renal and Metabolism Product Development at Roche #Cardiology #Hypertension #WorldHeartDay
-
To celebrate 20 years of World Lymphoma Awareness Day, the Lymphoma Coalition launched their #HonestTalk campaign earlier this month. This served as a vital reminder of the importance of conversations between patients, their families and healthcare teams to help manage the emotional stresses that come with lymphoma and the fear of relapse. Having these open conversations can help to foster stronger, more supportive relationships, address any concerns that may arise, and connect people to the most appropriate level of care. We encourage all people with lymphoma, as well as their families, friends and healthcare teams, to use the Honest Talk conversation starter and other helpful materials provided by the Lymphoma Coalition. #WLAD2024 #WLAD
This World Lymphoma Awareness Day, the global lymphoma community is encouraging everyone to have an Honest Talk. Living with lymphoma effects more than just physical health—it impacts emotional well-being too. It’s time to get honest about how we’re feeling and start conversations that lead to getting the support needed. If starting these conversations seems difficult, download our Honest Talk Conversation Starter. The digital postcard can be shared with medical teams or personal contacts to help open a dialogue. The Conversation Starter and other materials are available at https://lnkd.in/eKZYsRn4 #WLAD2024 #HonestTalk #lymsm
-
Earlier this month, we inaugurated our new pRED centre in Basel. We drew a lot of inspiration from our existing centres in Zurich, Munich, New York, and Welwyn when designing this centre so we can make this R&D facility the future of pharmaceutical innovation! 🔬 Designed for Discovery: Our new centre features thoughtfully crafted lab and office spaces, integrating team input to accelerate science, innovation, and collaboration. With novel digital solutions and seamless logistics, our scientists are equipped to push the boundaries of discovery. 🌍 Sustainability at its Core: Our commitment to the environment is evident throughout the facility, from energy-efficient designs to sustainable construction practices. 🧪 A Scientist’s Dream: Two high-rise laboratory buildings, an office building and a convention centre make up this one-of-a-kind complex and the perfect place to foster a culture of collaboration and creativity. With 103 patent applications filed in 2023 alone, this culture is flourishing! 👥 Building Connections: Our innovation thrives through partnerships with scientific and industry experts, academia, and patient groups. We aim to bring Basel’s vibrant scientific community together in our ultramodern facilities. ❤️ Patients First: Patients are at the heart of our mission. Our work at the pRED Center, which will continue to shape the future of healthcare and deliver life-changing medicines, is a testament to our collective dedication and expertise. Follow the link to learn more about our new centre and the exciting future we are building there. 👉 http://spkl.io/6043fKP2T
-
At Roche, we strive to develop innovations that deliver tangible improvements in healthcare while also reducing costs and environmental waste. Recently, our scientists have invented new technology to help diagnose respiratory illness. By using colour, temperature and relatively simple data processing, we can triple the number of viruses that can be detected in a patient sample with a single test, which could mean quicker results and treatment for patients. Find out more about the science behind 👉 http://spkl.io/6045fJqFX #Innovation #Diagnostics #Sustainability #ResearchAndDevelopment
-
Find out what Luis Paz-Ares, Head of Medical Oncology at Hospital Universitario 12 de Octubre, predicts for the future of cancer treatment: http://spkl.io/6048fJdEG Watch our ‘Cancer Dialogue’ video to hear renowned experts in oncology explore the latest avenues of cancer care and emerging trends.
-
Our team reflects the people we serve. We are dedicated to building a workforce that represents the patients and communities we support, with the aim of promoting fair access to healthcare. 💊🩺 Join us in this commitment to understanding and meeting the unique needs of our diverse population, ensuring that everyone receives the care and respect they deserve. Here you can find more information: https://lnkd.in/gRGEAEm8
-
-
Europe supports innovation. Right across the life cycle of a medicine. However, when a new purpose is found for age-old drugs, this brings potential new obligations to the Marketing Authorisation Holder (MAH). Having a voice in this process is important for innovators. Which is why we advocate for clarity on this within the draft #EUPharmaLegislation. For more see ⬇️
Verbundene Seiten
Ähnliche Seiten
Finanzierung
Roche
Insgesamt 4 Finanzierungsrunden
![]()
SoftBank
Weitere Informationen auf Crunchbase
Letzte Runde
Kapitalerhöhung nach Börsengang
Externer Crunchbase-Link für die letzte Finanzierungsrunde
5.000.000.000,00 $
Investor:innen